Recent Activity

Loading...

MDGL

Madrigal Pharmaceuticals, Inc. · NASDAQ

Performance

+6.35%

1W

-5.55%

1M

-5.61%

3M

+30.45%

6M

-4.89%

YTD

-20.81%

1Y

Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

Investment Analysis Report: MDGL

Overview

In this investment analysis report, we will delve into the financial statements of MDGL, a company in the Health Technology sector specializing in Pharmaceuticals. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow, capital ex...

See more ...

Technical Analysis of MDGL 2024-05-10

Overview:

In analyzing the technical indicators for MDGL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:

...
See more ...

Recent News & Updates